The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
Open accessAbstract
To enhance the strength of activation afforded by tumor antigen-specific receptors, we investigated the effect of adding combined CD28 and 4-1BB costimulatory signaling domains to a chimeric antigen receptor (CAR) specific for prostate-specific membrane antigen (PSMA). Having transferred receptors encompassing the CD28, 4-1BB, and/or CD3zeta cytoplasmic domains in primary human CD8(+) T cells, we find that the P28BBz receptor, which includes all three signaling domains, is superior to receptors that only include one or two of these domains in promoting cytokine release, in vivo T-cell survival and tumor elimination following intravenous T-cell administration to tumor-bearing severe combined immunodeficient (SCID)/beige mice. Upon in vitro exposure to PSMA, the P28BBZ receptor-induced the strongest PI(3)Kinase/Akt activation and Bcl-X(L) expression, and the least apoptosis in transduced peripheral blood CD8(+) T cells. These findings further support the concept of integrating optimized costimulatory properties into recombinant antigen receptors to augment the survival and function of genetically targeted T cells within the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487
TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
Watts, T. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115839 · Cited by 1,353
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Self-citationAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
Croft, M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1148 · Cited by 863
CD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
Staveley-O’Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., & Levitsky, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1178 · Cited by 704
Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
Self-citationTargeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Self-citationKowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
Self-citationGenetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintás-Cardama, A., Larson, S. M., & Sadelain, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0674 · Cited by 463
Self-citationCD28 extinction in human T cells: altered functions and the program of T‐cell senescence
Vallejo, A. N. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00256.x · Cited by 431
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
Weinberg, A. D., Rivera, M.-M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2160 · Cited by 387
Cannons, J. L., Lau, P., Ghumman, B., DeBenedette, M. A., Yagita, H., Okumura, K., & Watts, T. H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1313 · Cited by 355
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor-Papadimitriou, J., Burchell, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4901 · Cited by 346
Jones, R. G., Parsons, M., Bonnard, M., Chan, V. S. F., Yeh, W.-C., Woodgett, J. R., & Ohashi, P. S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.10.1721 · Cited by 329
CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
Saoulli, K., Lee, S. Y., Cannons, J. L., Yeh, W. C., Santana, A., Goldstein, M. D., Bangia, N., DeBenedette, M. A., Mak, T. W., Choi, Y., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1849 · Cited by 322
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Riley, J. L., & June, C. H. (2005) · Blood · doi:10.1182/blood-2004-04-1596 · Cited by 315
Stephan, M. T., Ponomarev, V., Brentjens, R. J., Chang, A. H., Dobrenkov, K. V., Heller, G., & Sadelain, M. (2007) · Nature Medicine · doi:10.1038/nm1676 · Cited by 299
Self-citationVera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., Wu, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017061 · Cited by 275
The PI‐3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3
Kane, L. P., & Weiss, A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00008.x · Cited by 260
Tan, J. T., Whitmire, J. K., Ahmed, R., Pearson, T. C., & Larsen, C. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4859 · Cited by 259
Hurtado, J. C., Kim, Y. J., & Kwon, B. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2600 · Cited by 257
Gong, M. C., Latouche, J.-B., Krause, A., Heston, W. D. W., Bander, N. H., & Sadelain, M. (1999) · Neoplasia · doi:10.1038/sj.neo.7900018 · Cited by 241
Self-citationMelero, I., Bach, N., Hellström, K. E., Aruffo, A., Mittler, R. S., & Chen, L. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199803)28:03<1116::aid-immu1116>3.0.co;2-a · Cited by 217
Wang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C. G., Till, B., Raubitschek, A., Forman, S. J., Qian, X., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.028 · Cited by 213
Zhang, H., Snyder, K. M., Suhoski, M. M., Maus, M. V., Kapoor, V., June, C. H., & Mackall, C. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4910 · Cited by 202
Haynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., & Darcy, P. K. (2002) · Blood · doi:10.1182/blood-2002-04-1041 · Cited by 197
Loskog, A., Giandomenico, V, Rossig, C., Pule, M., Dotti, G., & Brenner, M. K. (2006) · Leukemia · doi:10.1038/sj.leu.2404366 · Cited by 192
Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells
Latouche, J.-B., & Sadelain, M. (2000) · Nature Biotechnology · doi:10.1038/74455 · Cited by 175
Self-citationCutting Edge: Distinct Motifs Within CD28 Regulate T Cell Proliferation and Induction of Bcl-XL
Burr, J. S., Savage, N. D. L., Messah, G. E., Kimzey, S. L., Shaw, A. S., Arch, R. H., & Green, J. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5331 · Cited by 155
Qian, Y. R., Zhong, X., Flynn, D. C., Zheng, J. Z., Qiao, M., Wu, C., Dedhar, S., Shi, X., & Jiang, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208525 · Cited by 141
Self-citationRole of 4-1BB:4-1BB ligand in cancer immunotherapy
Cheuk, A., Mufti, G. J., & Guinn, B. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700670 · Cited by 136
Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling
Fruman, D. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.03.014 · Cited by 129
Guinn, B., Debenedette, M. A., Watts, T. H., & Berinstein, N. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.5003 · Cited by 125
Parry, R. V., Reif, K., Smith, G., Sansom, D. M., Hemmings, B. A., & Ward, S. G. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271006 · Cited by 122
Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes
Gade, T. P. F., Hassen, W., Santos, E. B., Gunset, G., Saudemont, A., Gong, M., Brentjens, R. J., Zhong, X.-S., Stephan, M. T., Stefanski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0436 · Cited by 117
Self-citationStärck, L., Scholz, C. W., Dörken, B., & Daniel, P. T. (2005) · European Journal of Immunology · doi:10.1002/eji.200425686 · Cited by 82
Couderc, B. C., Zitvogel, L., Douin‐Echinard, V., et al. (1998) · PubMed · Cited by 76
Moeller, M., Haynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Tanner, J. E., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., et al. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700710 · Cited by 62
Strome, S. E., Martin, B. A., Flies, D. B., Tamada, K., Chapoval, A. I., Sargent, D. J., Shu, S., & Chen, L. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200007000-00006 · Cited by 39
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationThe Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Self-citationHuman CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,074
Self-citation
Metadata
- Authors
- Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 18
- Issue
- 2
- Pages
- 413-420
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1984287161
- Cited by
- 543
- References
- 47
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.